📊 ANNX Key Takeaways
Is Annexon, Inc. (ANNX) a Good Investment?
Annexon is a pre-revenue biopharmaceutical company with severe cash burn ($140.4M operating cash outflow) and no commercial revenue, indicating the company is entirely dependent on external financing and successful clinical trial outcomes. The company's cash runway of approximately 1 year at current burn rates creates significant existential risk, and negative ROE of -98.1% reflects massive shareholder value destruction despite adequate liquidity from remaining cash reserves.
Annexon appears to be a pre-revenue biotech with no reported revenue, deep operating losses, and materially negative free cash flow, which makes the fundamentals highly dependent on future clinical and regulatory execution rather than current business performance. The balance sheet is relatively clean, with $139.42M of cash, no long-term debt, and strong liquidity ratios, but the current cash burn of roughly $140M per year implies limited runway without major operating improvement or additional capital.
Why Buy Annexon, Inc. Stock? ANNX Key Strengths
- Strong liquidity position with $139.4M cash and 4.42x current ratio provides near-term operational flexibility
- Zero long-term debt reduces financial leverage risk and interest burden
- Adequate stockholders' equity of $161.4M provides some balance sheet cushion for development phase operations
- Strong liquidity profile with a 4.42x current and quick ratio
- Large cash balance of $139.42M and no long-term debt
- Diluted EPS improved year over year, suggesting some per-share loss moderation
ANNX Stock Risks: Annexon, Inc. Investment Risks
- No revenue generation with pre-commercial pipeline creates zero near-term monetization pathway
- Unsustainable cash burn of $140.4M annually will exhaust cash reserves within 12 months without additional financing
- Severe negative returns (ROE -98.1%, ROA -69.1%) indicate clinical development failures or capital inefficiency requiring future dilutive financing
- High insider trading activity (18 Form 4 filings in 90 days) warrants investigation for potential negative signaling
- No revenue base, so there is no evidence yet of commercial traction or operating leverage
- Very large annual net loss and negative operating cash flow indicate heavy cash burn
- Cash runway looks tight relative to burn, increasing the risk of future dilution or financing needs
Key Metrics to Watch
- Operating cash flow trend and cash runway remaining before next financing event
- Clinical trial advancement and regulatory milestones for pipeline assets
- Capital raise activity, dilution, and per-share burn metrics
- Quarterly operating cash burn versus cash balance
- Any emergence of revenue and improvement in operating loss trend
Annexon, Inc. (ANNX) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 4.42x current ratio provides a solid financial cushion.
ANNX Profit Margin, ROE & Profitability Analysis
ANNX vs Healthcare Sector: How Annexon, Inc. Compares
How Annexon, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Annexon, Inc. Stock Overvalued? ANNX Valuation Analysis 2026
Based on fundamental analysis, Annexon, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Annexon, Inc. Balance Sheet: ANNX Debt, Cash & Liquidity
ANNX Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Annexon, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-1.01 indicates the company is currently unprofitable.
ANNX Revenue Growth, EPS Growth & YoY Performance
Annexon, Inc. Dividends, Buybacks & Capital Allocation
ANNX SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Annexon, Inc. (CIK: 0001528115)
📋 Recent SEC Filings
❓ Frequently Asked Questions about ANNX
What is the AI rating for ANNX?
Annexon, Inc. (ANNX) has a Combined AI Rating of SELL from Claude (STRONG SELL) and ChatGPT (SELL) with 88% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are ANNX's key strengths?
Claude: Strong liquidity position with $139.4M cash and 4.42x current ratio provides near-term operational flexibility. Zero long-term debt reduces financial leverage risk and interest burden. ChatGPT: Strong liquidity profile with a 4.42x current and quick ratio. Large cash balance of $139.42M and no long-term debt.
What are the risks of investing in ANNX?
Claude: No revenue generation with pre-commercial pipeline creates zero near-term monetization pathway. Unsustainable cash burn of $140.4M annually will exhaust cash reserves within 12 months without additional financing. ChatGPT: No revenue base, so there is no evidence yet of commercial traction or operating leverage. Very large annual net loss and negative operating cash flow indicate heavy cash burn.
What is ANNX's revenue and growth?
Annexon, Inc. reported revenue of N/A.
Does ANNX pay dividends?
Annexon, Inc. does not currently pay dividends.
Where can I find ANNX SEC filings?
Official SEC filings for Annexon, Inc. (CIK: 0001528115) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ANNX's EPS?
Annexon, Inc. has a diluted EPS of $-1.08.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is ANNX a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Annexon, Inc. has a SELL rating with 88% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is ANNX stock overvalued or undervalued?
Valuation metrics for ANNX: ROE of -98.1% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy ANNX stock in 2026?
Our dual AI analysis gives Annexon, Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is ANNX's free cash flow?
Annexon, Inc.'s operating cash flow is $-140.4M, with capital expenditures of $137.0K.
How does ANNX compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -98.1% (avg: 15%), current ratio 4.42 (avg: 2).